ethnic prevalence in the world. 4 These subtypes differ by one or more amino acid substitutions in the antigenic peptide-binding groove. Not every allelic variant is disease-associated, and the strength of association varies depending on the type of spondyloarthropathy and ethnicity of carriers. HLA-B*27:06 and HLA-B*27:09 have been reported not to be associated with AS and even considered to play a protective role. 5, 6 Based on the literature available on the Indian subjects, HLA-B*27:05 is the most common subtype followed by HLA-B*27:04.
Other common alleles reported from India are HLA-B*27:07, HLA-B*27:02, and HLA-B*27:10, all of which have been documented to be associated with AS. [7] [8] [9] [10] [11] [12] Serological techniques such as microcytotoxicity and flow cytometry for testing HLA-B27 require viable cells that adequately express HLA-B27 and may give false negative results if HLA-B27 is downregulated or "masked". 13 Flow cytometry, a widely used technique in India, is rapid, high-throughput and relatively inexpensive but has been reported to lack specificity, especially in the presence of antigens that cross-react with HLA-B27, such as HLA-B7 and HLA-B37. 14 Recently, molecular typing of HLA-B27 by polymerase chain reaction (PCR) is being commonly practiced increasingly as this technique relies on the detection of the HLA-B27-specific DNA sequence for the identification of B27 allele and is not influenced by conformational antigenic changes. The EUROArray HLA-B27 Direct, a microarray-based assay, is designed to detect all currently known HLA-B*27 subtypes and also indicates whether one of the nondisease-associated alleles HLA-B*27:06 and HLA-B*27:09 may be present in the respective sample. 15 Objectives of this study were (i) to evaluate flow cytometry method in comparison with DNA microarray for HLA-B27 typing and (ii) to evaluate EUROArray HLA-B27 Direct assay for HLA-B27 allele detection along with discrimination of AS/non-AS subtypes in Indian population.
Our study was not aimed to show association of HLA-B27 with disease predisposition.
| MATERIALS AND METHODS

| Patients
A total of 7543 patients with a presumptive clinical diagnosis of ankylosing spondylitis were referred to Metropolis Healthcare Ltd, Global
Reference Laboratory (GRL), Mumbai, India. The period of the study was 6 months that is, from December 2015 to May 2016. The study protocol was approved by Independent Ethics Committee. Peripheral blood was obtained from the study population, and all the samples were initially tested by flow cytometry within 24 hours of collection. Based on flow cytometry findings, samples were analyzed for the presence of HLA-B27 allele by microarray technology and later, a subset of samples were tested by DNA sequencing for identification of HLA-B27 subtypes.
| Flow cytometry analysis
The presence of HLA-B27 was detected by GS145.2 monoclonal antibody (HLA-B27 Kit; Becton Dickinson, San Jose, CA, USA). The BD HLA-B27 System consists of a combination of murine monoclonal antibodies Anti-HLA-B27 conjugated with fluorescein isothiocyanate (FITC) and CD3 conjugated with phycoerithrine (PE). The whole procedure was performed according to the manufacturer's instructions.
Whole blood samples were stained with anti-HLA-B27 antibody conjugated with fluorescein and with anti-CD3 antibody conjugated with phycoerythrin. Samples were incubated for 20 minutes in the dark, at room temperature, and then analyzed using a FACS Calibur flow cytometer on HLA-B27 v3.1 software (Becton Dickinson).
As per the manufacturer's instructions, based on the population tested, the cross-reactive samples fall on the positive side (+10 units) of the decision marker (148 MFI). This 10-channel zone is referred to as the "gray zone" for BD FACSCalibur and BD FACSCanto systems.
According to the manufacturer, samples falling within this zone should be confirmed by an alternate method. We termed this gray zone as "Manufacturer-Defined Equivocal Range" (MDER) of 148-157 MFI (mean fluorescence intensity), and all the cases falling within MDER were considered equivocal cases. To avoid misinterpretation and to obtain more clarity about the screening results, the MDER was extended on its lower side by 10 units, thereby redefining the MDER to 138-157 MFI. This extended range is termed "Laboratory-Defined
Equivocal Range" (LDER) in our study. 
| EUROArray HLA-B27 studies
| DNA sequencing studies
High-resolution HLA-B typing was carried out by Sanger sequencing. 
| RESULTS
| Flow cytometry
In this study, all the test samples were subjected to preliminary 
| Microarray results and comparison with flow cytometry
Of the overall cases (n = 1560) analyzed by microarray method, 1333 HLA-B*27:07 was thus the predominant subtype identified among the cases that showed positivity for ex2 only, and none of these 81 cases showed the presence of B*27:06 and B*27:09 alleles (Table 3) . Of the EUROArray negative cases (n = 227), 20 cases (18 flow cytometry equivocal cases and 2 flow cytometry positive cases)
were sequenced to obtain 14 cases of HLA-B*07 and 6 cases of HLA-B*37. Both the types, HLA-B7 and HLA-B37, are known to crossreact with HLA-B27.
| DISCUSSION
HLA-B27 is well known for its strong association with AS, a link discovered more than 40 years ago, and prevalence of AS mirrors the HLA-B27 prevalence across the world. [16] [17] [18] Excluding HLA-B27 virtually excludes the possibility of ankylosing spondilytis. 13 Serological techniques for HLA antigen detection include classic microcytotoxicity and flow cytometry. 19 Originally described by Terasaki and McClelland (1964) , microcytotoxicity was long-established method for HLA typing, but cross-reactivity induced HLA-typing errors and labor intensiveness limited its further use. 20 Flow cytometry is a rapid and relatively inexpensive method for preliminary screening of HLA antigen. However, in HLA serology, cross-reactivity is well known phenomenon as some human allo-antisera to HLA-B27 cross-react with the B7 antigen. One interesting feature in flow cytometry is that the cross-reactivity produced by HLA-B7 is so strong that it can mask not only other weaker cross-reactive HLA-B molecules but also even the presence of HLA-B27. 14 Besides B7, the antibody GS145.2 is known to cross-react to with HLA-B37, HLA-B44, and HLA-B55. T A B L E 4 (Continued) (Continues) results in the presence of HLA-B7 than is typing by molecular methods or microcytotoxicity. 
HLA-B*27:04, HLA-B*27:05, and HLA-B*27:07. 33 Several studies have reported the presence of HLA-B*27:06 or HLA-B*27:09 in the Italian and south-east Asian populations. Therefore, the ethnic background of patients, for whom the potential presence of the non-AS-associated alleles whenever indicated, should be identified. In our study cohort of patients from India, the 2 nondisease-associated alleles were not detected. This is consistent with previous findings ( Table 4 ) and means that the presence of the non-AS-associated alleles can be excluded with high probability for patients originating from India and being tested positive for HLA-B27 (exon 2 only).
In summary, a clinical laboratory should define its laboratoryspecific equivocal MFI range in comparison with molecular methods during initial flow cytometry method validation before using the assay for clinical testing of B27 as a primary screening method. Also, whenever the test result for a sample indicates the potential presence of a nondisease-associated allele (only exon 2 positive), it is prudent to know the ethnic background of the patient and HLA-B27 subtyping by DNA sequencing is recommended for patients belonging to nonIndian ethnic groups, specifically for patients from Italy and south-east Asia.
In conclusion, serological techniques such as microcytotoxicity and flow cytometry for testing HLA-B27 are rapid and relatively inexpensive but have been reported to lack specificity. HLA-B27 genotyping using molecular biology is a reliable but costly technique. Although EUROIMMUN's EUROArray HLA-B27 Direct assay is a cost and time-consuming molecular genetic assay, it successfully detects the presence of HLA-B27 subtype. DNA typing could be used as a complementary technique and applied to samples whose HLA-B27 phenotype cannot be determined by flow cytometry method. This approach of flow cytometry followed by DNA typing of equivocal cases is, in our experience, an economical and reliable approach in resource-limited developing countries like India.
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